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Abstract: Crossed cerebellar diaschisis (CCD) can be associated with impaired cerebrovascular reactivity
(CVR) and poor clinical outcome, but whether this holds true for patients with diffuse glioma is unknown.
With blood oxygenation level-dependent (BOLD)-CVR imaging, we determined the presence of CCD in
patients with diffuse glioma and investigated its relationship with cerebrovascular reactivity and clinical
outcome. For eighteen enrolled subjects (nineteen datasets) with diffuse glioma, CCD was deferred from
BOLD-CVR using a predetermined cerebellar asymmetry index (CAI) cutoff value of 6.0%. A FET-PET
study was done as a verification of the CCD diagnosis. BOLD-CVR values as well as clinical performance
scores (i.e., Karnofsky performance score (KPS), disability rating scale (DRS), and modified Rankin
scale (mRS)) by BOLD-CVR scan at 3-month clinical follow-up were assessed and compared for the
CCD-positive and CCD-negative group. CCD was present in 26.3% of subjects and strongly associated
with impaired BOLD-CVR of the affected (i.e., the hemisphere harboring the glioma) and unaffected
supratentorial hemisphere (CCD(+) vs. CCD(-): 0.08 ± 0.11 vs. 0.18 ± 0.04; p = 0.007 and 0.08 ± 0.12
vs. 0.19 ± 0.04; p = 0.007, respectively). This finding was independent of tumor volume (p = 0.48).
Furthermore, poorer initial (by scan) clinical performance scores at follow-up were found for the CCD(+)
group. The presence of crossed cerebellar diaschisis in patients with diffuse glioma is associated with
impaired supratentorial cerebrovascular reactivity and worse clinical outcome.
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Background: Crossed cerebellar diaschisis (CCD) can be associated with impaired cerebrovascular reactivity 
(CVR) and poor clinical outcome, but whether this holds true for patients with diffuse glioma is unknown. With 
blood-oxygenation level dependent (BOLD)-CVR imaging, we determined the presence of CCD in patients with 
diffuse glioma and investigated its relationship with cerebrovascular reactivity and clinical outcome. 
Methods: For eighteen enrolled subjects (nineteen datasets) with diffuse glioma, CCD was deferred from 
BOLD-CVR using a predetermined cerebellar asymmetry index (CAI) cut-off value of 6.0%. A FET-PET study 
was done as a verification of the CCD diagnosis. BOLD-CVR values as well as clinical performance scores (i.e. 
Karnofsky Performance Score (KPS), Disability Rating Scale (DRS), and modified Rankin Scale (mRS)) by 
BOLD-CVR scan and at 3-month clinical follow-up were assessed and compared for the CCD positive and CCD 
negative group.  
Results: CCD was present in 26.3% of subjects and strongly associated with impaired BOLD-CVR of the 
affected (i.e. the hemisphere harboring the glioma) and unaffected supratentorial hemisphere (CCD(+) vs. CCD(-
): 0.08±0.11 vs. 0.18±0.04; p=0.007 & 0.08±0.12 vs. 0.19±0.04; p=0.007, respectively). This finding was 
independent of tumor volume (p=0.48). Furthermore, poorer initial (by scan) clinical performance scores and at 
follow-up were found for the CCD(+)group. 
Conclusion: Presence of crossed cerebellar diaschisis in patients with diffuse glioma is associated with impaired 












In patients with diffuse glioma, crossed cerebellar diaschisis (CCD) – a depression of cerebral blood flow and 
metabolism in the cerebellar hemisphere contralateral to the supratentorial tumor – may potentially have 
important clinical and prognostic implications. [1]  
Previous investigations of diffuse glioma and CCD have focused on structural parameters like tumor location, 
tumor size and presence of edema, but lacked a comprehensive hemodynamic investigation, despite the fact that 
impaired cerebrovascular reactivity (CVR) may play a major role in CCD pathophysiology and clinical outcome. 
[2-4]  
Blood oxygenation-level dependent fMRI (BOLD)-CVR with a standardized carbon dioxide (CO2) stimulus [5, 
6] is a contemporary technique for investigating CVR impairment in patients with diffuse glioma. [7, 8] It has 
also shown its utility in accurately detecting CCD, albeit this has been mostly investigated in cerebrovascular 
patients. [3, 9]  
With BOLD-CVR and O-(2-[18F]fluoroethyl)-L tyrosine-Positron Emission Tomography (FET-PET) imaging, 
we determined the presence of CCD in patients diffuse glioma and investigated the relationship of CCD with 
cerebrovascular reactivity and clinical outcome.  
 
2 Materials and Methods 
At the University Hospital Zurich, patients with diffuse glioma according to the 2016 WHO classification [10] 
were selected from a prospective ‘BOLD-CVR glioma database’ based on the following inclusion criteria:  
subjects with age > 18 years that underwent a clinical metabolic FET-PET and BOLD-CVR imaging within six 
weeks. The diagnosis of diffuse glioma was confirmed with histopathological analysis for primary gliomas, and, 
where available, for recurrent gliomas. For the remaining recurrent gliomas, the diagnosis was done based on 
neuroimaging RANO criteria [11] and confirmed by interdisciplinary neuro-oncological tumor board.  
All the subjects signed an informed consent before they underwent a BOLD-CVR study. The Cantonal Ethics 
Committee of the Canton Zurich, Switzerland (KEK-ZH-Nr. 2012-0427) approved this study. The study was 
performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later 
amendments. Subjects with cerebellar vascular or oncological pathologies or subjects with medical (oncological 
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– chemotherapy), radiotherapeutic or surgical interventions between the BOLD-CVR and FET-PET examination 
were excluded from further analysis.  
 
2.1 Image Acquisition and Processing 
2.1.1 BOLD-CVR determination 
BOLD data and high resolution T1-imaging were acquired on a 3-tesla Skyra VD13 (Siemens Healthcare, 
Erlangen, Germany) with a 32-channel head coil. The imaging protocol for BOLD and a three dimensional (3D) 
T1-weighted Magnetization Prepared Rapid Acquisition Gradient Echo (MPRAGE) image was performed as 
published. [3]  
During the BOLD sequence, the carbon dioxide stimulus was modulated by a computer controlled gas blender 
with prospective gas targeting algorithms (RespirAct, Thornhill Research Institute, Toronto, Canada). [12] The 
RespirAct allows for precise targeting of arterial partial pressure of oxygen and CO2. All subjects were initially 
maintained on their resting CO2 baseline. The BOLD-CVR protocol consisting of clamping the subject on its 
initial resting baseline breathing for approximately 100 seconds, then inducing a hypercapnia (~10mmHg above 
resting CO2 baseline) for 80 seconds and a second 100 seconds of resting baseline. [3, 13] 
All the acquired BOLD volumes were transferred to an external computer and pre-processed with SPM 12 
(Statistical Parameter Mapping Software, Wellcome Department of Imaging Neuroscience, University College 
of London, London, UK). The BOLD fMRI volumes were pre-processed using time and motion-correction and 
normalized into Montreal Neurological Institute space. Last, a smoothing using a Gaussian Kernel of 6 was used. 
To determine BOLD-CVR, first a voxel-wise temporal shifting for optimal physiological correlation of the 
BOLD signal and CO2 time series was performed. Then, BOLD-CVR, defined as the percentage BOLD fMRI 
signal change/mmHg CO2, was calculated from the slope of a linear least square fit of the BOLD signal time 
course to the CO2 time course over the range of the whole protocol. Extra BOLD fMRI volumes (40 volumes) 
were acquired to allow for potential temporal shift. A more extensive description of the BOLD-CVR calculation 





2.2 Crossed cerebellar diaschisis determination  
2.2.1 BOLD-CVR cerebellar asymmetry index calculation to diagnose crossed 
cerebellar diaschisis 
For the BOLD-CVR volumes, a cerebellar asymmetry index ((CAI) ipsilateral hemisphere – contralateral-
crossed-hemisphere)/ipsilateral hemisphere * 100) was determined using a predefined cerebellar mask. 
Ipsilateral was defined as the side of the affected supratentorial hemisphere (i.e. the hemisphere harboring the 
glioma lesion). Derived from our previous study, CCD was diagnosed with a cut-off value of 6.0% CAI. [3] 
2.1.2 Corroborating FET-PET examination to verify the BOLD-CVR based crossed 
cerebellar diaschisis diagnosis  
Historically, PET examinations are considered the clinical reference standard to diagnose CCD. Here, presence 
of hypometabolism in the affected cerebellar hemisphere is considered pathognomonic for CCD. [14-16] For this 
study, FET-PET scans were performed according to our clinical standard on an ECAT EXACT HRþ scanner 
(Siemens Healthcare, Erlangen, Germany). The scanner acquired 63 contiguous transaxial planes, 
simultaneously covering 15.5 cm of axial field of view. After a 15-minute transmission scan (germanium-68 
sources), a target dose of 185 MBq of FET was injected intravenously. PET acquisition in 3-dimensional mode 
was started 30-40 minutes after injection (128 _ 128 matrix). Data were reconstructed by filtered back-projection 
using a Hann filter after correction for scatter and attenuation.  
In a similar fashion as for the BOLD fMRI images, a CAI was determined for the FET-PET images. To allow for 
an optimal normalization of the PET images to MNI space, the PET images were first coregistered to the mean 
BOLD fMRI image, which was created during motion correction of the BOLD fMRI images. The normalization 
to MNI space was then done with the same SPM algorithm as for the BOLD fMRI images.  
2.1.4 Volume of interest determination 
Three-dimensional tumor masks were determined and manually drawn from the current state-of-the-art MRI 
protocol by a neuroradiologist with >20 years of experience (A.P.) using iPlan software (BrainLab AG, Munich, 
Germany).  The tumor borders were drawn on every slice where the tumor was visible on the T1-weighted 
contrast enhanced scans or on every slice of FLAIR and/or T2 sequences in the case of absent contrast enhanced 
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lesion, obtaining a 3-dimensional spherical volume of interest. These tumor masks were overlaid on the BOLD-
CVR maps to obtain mean intralesional values in those specific regions.  
 
2.2 Assessment of clinical performance status and neurological outcome  
The Karnofsky performance status (KPS) and Disability Rating Scale (DRS) were used to evaluate the 
performance status at moment of scan for glioma or recurrent tumor, and at 3-month follow-up. To assess the 
neurological status initially and at 3-month follow-up, modified Rankin scale (mRS) values were determined. 
 
2.3 Statistical analysis 
We performed the statistical analysis using SPSS Statistics 26 (IBM Corp., Armonk, NY). All normally 
distributed continuous variables are reported as mean ± standard deviation (SD). Categorical ordinal variables 
are presented as median (interquartile range) whereas dichotomous variables are shown as frequency (%). Means 
of normally distributed continuous variables from the CCD-positive and CCD-negative groups were compared 
by an independent Student's 2-tailed t test, where p< 0.05 was considered statistically significant. ANCOVA was 
used to statistically control the effect of covariates (WHO grade and primary/recurrent tumor) for BOLD-CVR 
findings between CCD(+) and CCD(-) group.  Tumor volume was used as covariate to correct the impact on 
clinical outcome and performance status between CCD(+) and CCD(-) group. To identify a relationship between 
the whole cohort BOLD-CVRCAI, whole brain CVR and clinical status by BOLD-CVR scan as well as outcome 
after three months using KPS, DRS and mRS, we used a Spearman Rank-order correlation analysis with partial 













3.1 Study population characteristics 
A flow-chart illustrating patient inclusion can be found in Figure 1. The 18 included diffuse glioma patients had 
the following specific diagnoses: primary or recurrent IDH mutant, 1p/19-codeleted anaplastic 
oligodendroglioma (n=9), IDH mutant anaplastic astrocytoma (n=2) or IDH wildtype glioblastoma (n=7). The 
mean age was 52.4±12.3 years, and 84% of the subjects were male. Relevant clinical and baseline characteristics 
of the study population are presented in Table 1 and in the supplemental file (Table 1). No significant differences 
between CCD(+) and CCD(-) subjects were seen in primary/recurrence tumor, tumor location, histological 
grade, and molecular analysis (Table 1). 
 
3.2 CCD determination with BOLD-CVR and verification with FET-PET 
Using BOLD-CVR as the reference imaging standard [3], five subjects (26.3%) with diffuse gliomas were 
classified as CCD positive (CCD(+)). Representative illustrations of one subject each with and without CCD are 
given in Figure 2.  
The PET CAI showed a difference (3.69±5.09 vs. 1.06±2.35, p=0.04) between the CCD(+) and CCD(-) groups, 
indicating, on average, less metabolic activity in the CCD affected cerebellar hemisphere. The affected (crossed) 
cerebellar hemisphere exhibited lower CVR values in CCD(+) group (CCD(+) vs. CCD(-): 0.08±0.12 vs. 
0.19±0.04, p=0.005) as well as the unaffected (ipsilateral) cerebellar hemisphere did (CCD(+) vs. CCD(-): 
0.11±0.12 vs. 0.19±0.05, p=0.04).  
3.3  BOLD-CVR findings in patients with and without CCD 
For the supratentorial brain region, CCD(+) patients showed significantly more impaired whole brain CVR 
(CCD(+) vs. CCD(-): 0.08±0.12 vs. 0.18±0.03, p=0.04) as well as CVR within both the affected (CCD(+) vs. 
CCD(-): 0.08±0.11 vs. 0.18±0.04, p=0.03) , as well as the unaffected (CCD(+) vs. CCD(-): 0.08±0.12 vs. 
0.19±0.04, p=0.04) supratentorial hemisphere as compared to CCD(-) subjects, corrected for tumor grade and 
primary/recurrence tumor presentation as possible biases  (Table 2). These differences were independent of 




3.4 Clinical performance status and outcome 
Significant differences between CCD(+) and CCD(-) group were seen for initial (collected by BOLD-CVR scan)  
KPS and DRS by diagnosis of primary diffuse glioma or by first diagnosis of tumor recurrence. This significant 
difference in both clinical scores persisted at 3-month follow-up (Table 3).  
Table 4 shows the association between BOLD-CVR findings and clinical scores for the whole cohort (19 
datasets of 18 patients). Despite tumor volume correction, BOLD-CVR CAI had a strong positive correlation 
with all clinical scores by scan (p-values for KPS, mRS and DRS: 0.04, 0.05, 0.02, respectively) and by 3-month 
follow up (p-values for KPS, mRS and DRS: 0.03, 0.05, 0.02, respectively), indicating that a larger cerebellar 
difference was associated with higher scores. Impaired supratentorial BOLD-CVR was still associated with poor 
initial (by BOLD-CVR scan) clinical performance after tumor volume correction (p-values for KPS, mRS and 




In our study, the presence of crossed cerebellar diaschisis in patients with diffuse glioma is associated with 
severely impaired supratentorial cerebrovascular reactivity, and worse clinical outcome at 3-month follow-up. 
By using BOLD-CVR, CCD was diagnosed in 26.3% of subjects, which was confirmed with FET-PET imaging 
demonstrating marked hypometabolism in the affected – crossed – cerebellar hemisphere for these patients. 
Interestingly, the presence of CCD showed a significant BOLD-CVR impairment in both the tumor affected and 
unaffected supratentorial hemisphere, independent of tumor volume and corrected for tumor grade and 
primary/recurrence tumor presentation as possible biases.  
 
4.1 Meaning of impaired supratentorial BOLD-CVR in diffuse glioma patients exhibiting 
crossed cerebellar diaschisis 
The globally supratentorial impaired BOLD-CVR in the CCD(+) group is a finding in concordance to an earlier 
study done in cerebrovascular steno-occlusive patients [3], where impaired BOLD-CVR was now not only seen 
in the affected supratentorial hemisphere (i.e. the hemisphere harboring glioma) but also in the unaffected 
hemisphere. In contrast to steno-occlusive disease where after an infarction the trend is generally toward brain 
repair and functional recovery, diffuse gliomas are dynamic entities which grow, invade and produce progressive 
9 
 
structural and functional deficits. [16-18]  Due to their infiltrative nature, the biggest issue in patients with 
diffuse glioma is tumor border delineation as tumor infiltration outside the contrast-enhancement is often 
unclear. The bilateral BOLD-CVR impairment in CCD(+) patients show that CCD is associated with a more 
global hemodynamic effect of the tumor on brain tissue outside of its visual tumor borders. This was also found 
by Liu et al. [2] who showed more widespread perfusion and structural impairments in glioma patients with 
CCD.  A recent paper showed the integration of tumor cells into neural circuits in the brain. [19] Activation of 
neurons will cause vasodilatation due to physiological neurovascular coupling [20, 21], which will reduce the 
CVR. In addition, blood flow recruitment to these brain regions will also result in a CVR decrease in other areas. 
[22, 23]  
Others have investigated supratentorial structural deficits in glioma patients with CCD and shown that CCD in 
cerebral gliomas was associated with the pathological grade and lesion size, supporting the concept that diffuse 
gliomas with more remote effects are more likely to cause CCD. [2]  We did not find an increase in lesion size to 
differ between patients with and patients without CCD; however, lesion size presented in the prior paper 
included cerebral edema, making it a broader variable more likely to include infiltration and tumor invasiveness.  
The glioma grading represents primarily the invasiveness of glioma to infiltrate surrounding tissue. In an earlier 
paper, we have shown that increasing tumor volume and edema presents with more supratentorial BOLD-CVR 
impairment. [24] There may, therefore, be a strong interaction between impaired supratentorial BOLD-CVR and 
the presence of CCD. This finding supports our previously published theory about hemodynamic-induced CCD. 
[3] As seen in the supplemental file, Table 1, not all diffuse gliomas are anatomically located in the area where 
the fibers of cortico-ponto-cerebellar tract run, so lesion-induced CCD, as published by Baron [15], cannot be the 
pathophysiological explanation of (all) our results. Therefore, the overall significantly impaired supratentorial 
CVR in the CCD(+) group confirms the postulated hemodynamic origin of remote cerebellar impairment in 
patients with diffuse glioma. Moreover, impaired supratentorial hemodynamic could lead to supratentorial 
hemispheric atrophy, as already seen in patients with supratentorial disease in whom CCD was suggested by 
PET. [25]  This would support the ‘hibernating brain’ theory as seen in chronic steno-occlusive patients. [26] 
 
4.2 Clinical meaning of crossed cerebellar diaschisis in diffuse glioma patients 
The indication of a more widespread effect of the tumor on the brain in patients with CCD is congruent with 
findings of worse clinical status and a worse prognosis. Already in the 1990s, the presence of CCD was 
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correlated to an increased likelihood of motor impairment [16], a finding which is related to higher NIHSS and 
functional scores such as the KPS in patients with CCD in our study. Moreover, others investigating the 
prognostic value of CCD in diffuse glioma patients reported reduced survival in patients with CCD. [9] This 
strong impact of impaired cerebral hemodynamic on clinical outcome could be (partly) explained by the recently 
published study, which postulated that tumor cells behave like neurons.[19] This study, for the first time, showed 
that tumor cells integrate into neural circuits in the brain [19], a finding which can explain while those tumors 
exhibit not only a locally impaired cerebral hemodynamic, but have an impact on whole brain too, as seen in our 
cohort. With the knowledge that tumor cells integrate into the neural circuit, the impaired supratentorial 
hemodynamic can be explained. The impaired hemodynamic causes CCD as well as worse neurological status 
and outcome. Both oncological scores (KPS and DRS) showed clear statistical difference with worse initial 
status and worse 3-month outcome for CCD(+) group compared to CCD(-) group, even after correction for 
tumor volume.  
This may indicate that CCD could be used as a novel parameter for prognostic models and may have the 
potential to strengthen future clinical prediction algorithms because of its unique capability to test occult tumor 
invasiveness.   If taken together, the presence of CCD in patients with diffuse glioma may, therefore, be a 
reflection of the extent of tumor infiltration outside its visible borders as seen in T1-weighted contrast enhanced 
scans or on FLAIR and/or T2 sequences and potentially be used in future models as a surrogate imaging marker 
of tumor invasiveness. Moreover, additional imaging parameters such as perfusion MRI, MR spectroscopy, 
diffusion-weighted imaging (DWI) and susceptibility-weighted imaging (SWI), should be analyzed to provide 
additional information about the most aggressively growing parts of diffuse gliomas and their infiltration. To 
study and evaluate these suspicions, larger studies are needed.  
5 Limitations 
 
Our data must be interpreted in the context of the study design. First, the study cohort was small (i.e., 19 datasets 
from 18 patients), but in concordance with other CCD studies in glioma patients. [2, 16, 24] Moreover, we have 
only included five patients with CCD and, therefore, the results should be interpreted with caution. However, 
due to the strong associations found, we believe these results are indicative. Since including 19 datasets from 18 
patients, we were able to correct for two variances that could influence our CVR results - we corrected for WHO 
tumor grade as well as for primary/recurrent tumor and did not correct for previous chemotherapy treatment, 
which could affect the blood-brain-barrier and the tumor hemodynamic. Secondly, this was a retrospective 
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analysis of prospectively collected data stored in a database. Caution should also be taken, regarding the clinical 
and prognostic validity of a CCD diagnosis as all studies were undertaken with a rather small cohort. Larger 
studies are necessary to confirm these findings. As the clinical correlation of CCD should be further elucidated, 
it is also imperative to better understand longitudinal structural and hemodynamic changes within brain remote 
from the area of primary lesion. Similarly, as seen in other recent BOLD CVR studies in steno-occlusive disease 
[3, 9], the cerebral blood flow asymmetry values used to define CCD were based on a region covering a large 
portion of the cerebellum. Decreased CVR values and hypometabolism are not present for the whole cerebellar 
hemisphere (as can be seen in Figure 2B). A more detailed analysis of cerebellar anatomical and functional areas 
may therefore be considered in future work investigating CCD in diffuse glioma. 
6 Conclusion 
 
Presence of crossed cerebellar diaschisis in patients with diffuse glioma is associated with impaired 
supratentorial cerebrovascular reactivity, and worse clinical outcome. 
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Figure 1: Study flow chart 
 
Caption: From the prospective ‘BOLD-CVR database’, we extracted 60 patients with glioma who underwent 
BOLD-CVR imaging at first diagnosis of tumor or at diagnosis of tumor recurrence. From 60 glioma patients, 24 
patients underwent BOLD and FET-PET imaging prior to treatment (no treatment (i.e., no surgery) done for 
primary diffuse gliomas, no second line therapy initiated for recurrent diffuse glioma) in time frame of six 
weeks. Two patients with non-diffuse gliomas and three patients with > 6 weeks interval between BOLD-CVR 
and PET scans were excluded from the study. Eighteen patients with 19 datasets (one patient underwent the 
protocol twice - initial and by tumor recurrence) with diffuse glioma (either IDH mutant WHO grade III or IDH 
wildtype WHO grade IV) were eligible for further analysis (one patient underwent the protocol twice - initial and 
by tumor recurrence). The diagnosis was confirmed with histopathological analysis for primary gliomas and, 
where available, for recurrent gliomas.  
Abbreviations: BOLD: blood oxygenation-level dependent, CVR: cerebrovascular reactivity, defined as 
percentage BOLD signal change per mmHg CO2, FET-PET = O-(2-[18F]fluoroethyl)-L tyrosine-Positron 
Emission Tomography; WHO: World Health Organization. 
 
Figure 2: Exemplary images of CCD(+) and CCD(-) patient 
Caption:  
A.  A 48-year-old male patients with right sided frontal glioblastoma (IDH wildtype WHO grade IV), first 
diagnosed and subtotal resected in August 2017. In February 2018, the patient presented with recurrent 
tumor frontal on the right side as seen in contrast-enhanced T1-weighted images. He presented with 
psychomotor slowing-down and frontal lobe syndrome (Karnofsky 80%, DRS 2 and mRS 2).  He 
underwent a BOLD-CVR and FET-PET study in a timeframe of 12 days.  
B. BOLD-CVR showed hemispherical impaired CVR (white arrow) clearly beyond the tumor borders as 
well as impaired CVR of the contralateral hemisphere. In his cerebellum, cerebellar asymmetry can be 
appreciated contralateral to the supratentorial tumor recurrence, i.e., crossed cerebellar diaschisis (white 
arrow on bottom images). 
C. FET PET images confirmed a hypermetabolic recurrent tumor lesion (white arrow). In his cerebellum, 
crossed cerebellar diaschisis (white arrow on bottom images) is appreciated with good spatial 
15 
 
agreement between both imaging modalities. After three months, he showed a slight worsening of his 
condition (Karnofsky 70%, DRS 2 and mRS 2). 
 
D. A 64-year-old male patients with contrast-enhancing tumor on T1-weighted images in the left 
supramarginal gyrus. He underwent a BOLD-CVR and FET-PET study in a time frame of 23 days. He 
presented with incomplete angular gyrus syndrome (Karnofsky 80%, DRS 1 and mRS 2). After total 
resection, the histopathological examination confirmed the diagnosis of glioblastoma (IDH wildtype 
WHO grade IV). 
E.  The pre-operative BOLD-CVR showed locally impaired CVR (white arrow). No crossed cerebellar 
diaschisis is observed in BOLD-CVR images. 
F. The pre-operative FET PET images confirmed a hypermetabolic tumor lesion (white arrow). Similarly, 
no crossed cerebellar diaschisis is observed in FET-PET images. After three months, he presented with 
improved overall and neurological condition (Karnofsky 90%, DRS 1 and mRS 1). 
Abbreviations: BOLD: blood oxygenation-level dependent, CCD: crossed cerebellar diaschisis, 
CVR: cerebrovascular reactivity, defined as percentage BOLD signal change per mmHg CO2, DRS: 
disability rating scale, mRS: modified Rankin scale, FET-PET: O-(2-[18F]fluoroethyl)-L tyrosine-Positron 
Emission Tomography; SUV: standardized uptake value; WHO: World Health Organization. 
 
Supplemental file 1:  Subject characteristics 
Case Age  
(years) 



















1 39 M Left frontal Anaplastic astrocytoma  
(WHO III) 
Recurrence CCD(-) 14.76 No temozolomide 
  2* 53 M Right frontal Anaplastic oligodendroglioma  
(WHO III) 
Recurrence CCD(-) 3.25 No PCV 
 
3 32 F Right temporal Anaplastic astrocytoma  
(WHO III) 
Recurrence CCD(-) 2.55 No none 
4 63 M Left temporal Glioblastoma  
(WHO IV) 
Primary CCD(-) 4.33 Yes / 
5 37 M Right frontal Anaplastic oligodendroglioma  
(WHO III) 
Primary CCD(-) 105.10 No / 
6 45 M Right temporo-
parietal 
Anaplastic oligodendroglioma  
(WHO III) 
Recurrence CCD(-) 40.69 No none 
7 70 F Right frontal Glioblastoma  
(WHO IV) 
Primary CCD(-) 18.78 Yes / 
8 61 F Left parietal Glioblastoma  
(WHO IV) 
Recurrence CCD(-) 0.12 No temozolomide, 
study 
medication 
9 52 M Left frontal Anaplastic oligodendroglioma  
(WHO III) 
Primary CCD(-) 5.79 No / 
10 52 M Left frontal Anaplastic oligodendroglioma  
(WHO III) 
Recurrence CCD(+) 0.92 No Temozolomide 




Recurrence CCD(-) 5.73 No Temozolomide 
12 60 M Right frontal Anaplastic oligodendroglioma 
(WHO III) 
Recurrence CCD(-) 0.80 No PCV 
13 59 M Right frontal Anaplastic oligodendroglioma 
(WHO III) 
Recurrence CCD(-) 1.11 No Temozolomide 
14 28 M Right frontal Anaplastic oligodendroglioma 
(WHO III) 
Recurrence CCD(-) 0.19 No PCV 
15 49 M Right frontal Glioblastoma  
(WHO IV) 
Recurrence CCD(+) 15.48 Yes Temozolomide 
16 48 M Left temporal Anaplastic oligodendroglioma 
(WHO III) 
Recurrence CCD(-) 40.54 No Temozolomide 






Primary CCD(+) 7.45 Yes / 
18 68 M Right temporal Glioblastoma  
(WHO IV) 
Primary CCD(+) 10.03 Yes / 
19* 51 M Right frontal Anaplastic oligodendroglioma 
(WHO III) 
Primary CCD(+) 146.70 No / 
*the patient underwent the protocol two times (initial and by tumor recurrence) 
BOLD: blood-oxygenation level dependent , PCV: procarbazine, lomustine and vincristine, PET: Positron Emission Tomography WHO: World Health Organization 
 
Table 1. CCD according to BOLD-CVR: Relevant clinical and baseline characteristics  









Age (mean ± SD) 52.4 ± 12.3 57.5 ± 11.5 50.6 ± 12.4 0.30 
Male  16 (84.2)  5(100) 11(78.6) 0.29 
Smoking   4 (21.1) 0 3(21.4) 0.95 
Primary  7 (36.8) 3(60) 4(28.6) 0.23 
Right hemispheric  11 (57.9) 3(60) 7(50) 0.92 
Frontal lobe tumor  10 (52.6) 2(40) 7(50) 0.54 
WHO Grade IV  7 (36.8) 3(60) 4(28.6) 0.23 
MGMT promotor methylated  4 (21.1) 1(20) 3(21.4) 0.99 
IDH1 mutation  12 (63.2) 2(40) 10(71.4) 0.23 
ATRX loss  7 (36.8) 2(40) 5(35.7) 0.95 
1p/19q deletion  10 (52.6) 1(20) 9(64.3) 0.51 
All data are presented as n (%) unless stated otherwise. ATRX = α thalassemia/mental retardation syndrome X-linked, IDH = isocitrate dehydrogenase, LOH = loss 




















Table 2. CCD according to BOLD-CVR: BOLD-CVR and PET findings 
Functional measurement 
(mean ± standard deviation) 
Total cohort  
(n=19) 
 Crossed cerebellar 
diaschisis positive 
group (n=5) 




Mean BOLD-CVR whole brain 0.16 ± 0.08 0.08 ± 0.12 0.18 ± 0.03 0.04* 
Mean CVR grey matter 0.18 ± 0.08 0.10 ± 0.13 0.21 ± 0.04 0.05* 
Mean CVR white matter 0.11 ± 0.07 0.04 ± 0.11 0.13 ± 0.02 0.05* 
Mean BOLD-CVR affected 
supratentorial hemisphere 
0.15 ± 0.08 0.08 ± 0.11 0.18 ± 0.04 0.03* 
Mean BOLD-CVR unaffected 
supratentorial hemisphere 
0.16 ± 0.08 0.08 ± 0.12 0.19 ± 0.04 0.04* 
FET-PET CAI (%) 1.79 ± 3.66 3.69 ± 5.09 1.06 ± 2.35 0.04 
Tumor volume (cm3) 22.33 ± 39.06 36.12 ± 62.04 17.41 ± 28.79 0.37 
BOLD-CVR tumor 0.03 ± 0.07 0.01 ± 0.10 0.04 ± 0.05 0.86* 
*using ANCOVA corrected for WHO grade and primary/recurrent tumor as possible covariate  
BOLD = blood-oxygenation level dependent; CAI = cerebellar asymmetry index; CVR = cerebrovascular reactivity, defined as percentage BOLD signal change per 






















Table 3: Clinical performance status and outcome 
Clinical outcome  
(median(interquartile)) 
Total cohort  
(n=19) 
 Crossed cerebellar 
diaschisis positive 
group (n=5) 




KPS scan 90(10) 80(20) 90(10) 0.02* 
mRS scan 1(1) 2(2) 1(1) 0.12* 
DRS scan 1(1) 2(3) 1(1) 0.03* 
KPS 3 months 80(20) 70(20) 90(20) 0.03* 
mRS 3 months 2(1) 2(1) 1(1) 0.13* 
DRS 3 months 2(1) 3(3) 1(1) 0.01* 
*using ANCOVA corrected for tumor volume as possible covariate  


























Table 4: Spearman-Rank correlation for whole cohort (n=19) with partial correction for tumor volume  















BOLD-CVR CAI 0.04 0.05 0.02 0.03 0.05 0.02 
BOLD-CVR whole brain 0.01 0.004 0.03 0.54 0.68 0.77 
BOLD = blood-oxygenation level dependent; CAI = cerebellar asymmetry index; CVR = cerebrovascular reactivity, defined as percentage BOLD signal change per 
mmHg CO2; DRS = disability rating scale; KPS = Karnofsky performance status; mRS = modified Rankin scale. 
 


